Moderna's Roller Coaster: What $1,000 at Every Stage Would Be Worth
No stock tells the story of the 2020s better than Moderna. A $20 billion biotech that became a $200 billion pandemic hero, then crashed more than 80% from its peak, and is now attempting a comeback with a pipeline beyond COVID vaccines. The "what if" depends entirely on when you got in.
Three entry points, three very different outcomes
The pre-COVID bet (2018)
$1,000 in Moderna in 2018 is worth about $4,586 today. That's a +358.6% return. Not bad, but it hides a wild ride. That $1,000 briefly hit over $25,204 at Moderna's September 2021 peak of $384.86 per share. Then it crashed. If you held through the entire roller coaster, you're still up - but you gave back roughly 82% of your peak gains as of the latest close.
The pandemic entry (2020)
$1,000 in early 2020 is worth $3,414. You caught Moderna right before the pandemic made mRNA a household term. COVID vaccines generated $36 billion in revenue over two years. But the stock peaked in September 2021 and spent years declining as vaccine demand fell, before rallying again in 2026.
The late entry (2023)
$1,000 in 2023 is worth just $398. That's a -60.2% loss. You bought after the initial crash but before the stock fell further as COVID booster uptake disappointed and Moderna's cancer vaccine pipeline was still years from revenue.
The 2026 rebound
The turnaround story exists on paper: the RSV vaccine launched, the flu-COVID combo vaccine is in late trials, and the cancer vaccine partnership with Merck is showing promising data. The mRNA platform that made COVID vaccines is now being applied to oncology, rare diseases, and autoimmune conditions. And the stock has started moving with it: Moderna is up 137.5% year-to-date in 2026, though it still sits roughly 82% below its September 2021 peak.
Whether this rebound holds up depends on pipeline execution, not pandemic demand, and one strong year-to-date is not yet proof of it. Moderna's story is a reminder that timing matters enormously - and that the "right" stock at the "wrong" time can still lose you money.
See how Moderna compares to other healthcare stocks like Eli Lilly and Intuitive Surgical, or read about other worst-case timing scenarios.